

**JOURNAL-BASED CME ARTICLE**

# Short Versus Long Course of Antibiotics for Catheter-Associated Urinary Tract Infections in Patients With Spinal Cord Injury: A Randomized Controlled Noninferiority Trial



Rabih O. Darouiche, MD,<sup>a,b,c,d</sup> Mayar Al Mohajer, MD,<sup>e</sup> Danish M. Siddiq, MD,<sup>b,d</sup> Charles G. Minard, PhD<sup>f</sup>

From the <sup>a</sup>Spinal Cord Injury Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX; <sup>b</sup>Section of Infectious Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX; <sup>c</sup>Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX; <sup>d</sup>Department of Medicine, Baylor College of Medicine, Houston, TX; <sup>e</sup>Department of Medicine, University of Arizona, Tucson, AZ; and <sup>f</sup>Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX.

**Statement of Need:**

Urinary tract infection (UTI) is the most common hospital acquired infection in patients with spinal cord injury (SCI). In general, catheter-associated urinary tract infection (CA-UTI) can lead to serious medical complications, prolong hospitalization, and incur tremendous cost. More than 90% of cases of bacteriuria in patients with SCI who use an indwelling bladder catheter are asymptomatic. The management of CA-UTI has not been standardized in patients with SCI with respect to (1) the need to immediately replace the indwelling catheter, (2) the necessity to provide antibiotic coverage against all organisms grown from urine cultures, and (3) the duration of antibiotic treatment. This activity provides information on the role of catheter discontinuation and the higher rates of clinical improvement and lower rates of symptomatic relapse.

This journal-based activity has been planned and developed in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Professional Education Services Group (PESG).

**Accreditation Statement:**

Professional Education Services Group (PESG) is accredited by the ACCME to provide continuing medical education (CME) for physicians.

**Credit Designation Statement:**

PESG designates this Journal-based CME activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals completing continuing education credit for this activity will be issued a certificate of participation.

**Educational Objectives:**

To support the attainment of knowledge, competence, and performance, the learner should be able to achieve the following objectives:

1. To assess the applicability of a short-course regimen of antibiotics for managing catheter-associated urinary tract infection (CA-UTI) in patients with spinal cord injury (SCI).
2. Identify causative agents for infections and appropriate treatment options.
3. Evaluate options for catheter exchange in patients with spinal cord injury (SCI).

**Planning Committee**

Rabih O. Darouiche MD, Mayar Al Mohajer MD, Danish M. Siddiq MD, Charles G. Minard PhD, PESG staff, ACRM Editorial Office Staff.

**Faculty Profiles & Disclosure Information**

As a provider accredited by the ACCME, it is the policy of PESG to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty and planners of this educational activity disclose the following:

**Rabih O. Darouiche**

Spinal Cord Injury Care Line, and Section of Infectious Diseases  
Michael E. DeBakey Veterans Affairs Medical Center  
Houston, TX

Department of Physical Medicine and Rehabilitation, and Department of Medicine  
Baylor College of Medicine  
Houston, TX

No relevant financial relationships to disclose

**Mayar Al Mohajer**

Department of Medicine  
University of Arizona  
Tucson, AZ

No relevant financial relationships to disclose

**Danish M. Siddiq**

Section of Infectious Diseases  
Michael E. DeBakey Veterans Affairs Medical Center  
Houston, TX  
Department of Medicine  
Baylor College of Medicine  
Houston, TX

No relevant financial relationships to disclose

**Charles G. Minard**

Dan L. Duncan Institute for Clinical and Translational Research  
Baylor College of Medicine  
Houston, TX

No relevant financial relationships to disclose

**PESG Staff**

No relevant financial relationships to disclose.

**Leighton Chan, MD, MPH**

Co-Editor-in-Chief, Archives of Physical Medicine and Rehabilitation  
Bethesda, MD

No relevant financial relationships to disclose.

**ACRM Editorial Office Staff**

No relevant financial relationships to disclose.

**Resolution of Conflict of Interest**

PESG has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, PESG has resolved the conflict by external content review.

**Unapproved/Off-Label Use Disclosure**

PESG requires CME faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

**Intended Audience**

This program is intended for physicians and healthcare professionals responsible for the comprehensive care for individuals with chronic illness and disabilities.

### Method of Participation

In order to claim credit, participants must complete the following:

1. Read the activity
2. Complete the CME Test and Evaluation. Participants must achieve a score of 70% on the CME Test.

Participants can complete the CME Test and Evaluation online by logging on to <http://acrm.cds.pesgce.com>. Upon successful completion

of the online tests and evaluation form, you can instantly download and print your certificate of credit.

#### CME Inquiries

For all CME certificate inquiries, please contact us at [support@pesgce.com](mailto:support@pesgce.com).

This continuing education activity is active starting February 1, 2014 and will expire January 31, 2015.

Estimated time to complete this activity – 1.0 hours

### Abstract

**Objective:** To assess the applicability of a short-course regimen of antibiotics for managing catheter-associated urinary tract infection (CA-UTI) in patients with spinal cord injury (SCI).

**Design:** Randomized, controlled, noninferiority trial.

**Setting:** Medical center.

**Participants:** Patients with SCI who had CA-UTI (N=61).

**Interventions:** Patients were randomized to receive either a 5-day regimen of antibiotics after catheter exchange (experimental group) or a 10-day regimen of antibiotics with catheter retention (control group). Noninferiority was prespecified with a margin of 10%.

**Main Outcome Measure:** Clinical cure at the end of therapy.

**Results:** Of the 61 patients enrolled in this study, 6 patients were excluded because of bacteremia or absence of urinary symptoms. All patients (100%) achieved clinical cure at the end of therapy. The rates of microbiologic response were 82.1% in the experimental group and 88.9% in the control group (upper boundary 95% confidence interval (CI) for difference, 26%). The rates of resolution of pyuria were 89.3% in the experimental group and 88.9% in the control group (upper boundary 95% CI for difference, 16%). Patients in the experimental group had higher rates of CA-UTI recurrence than the control group. The rates of new CA-UTI, diarrhea, and *Clostridium difficile* colitis were similar in the 2 treatment arms.

**Conclusions:** The primary endpoint of the study was met, indicating that the 5-day regimen with catheter exchange was noninferior to the 10-day regimen with catheter retention on the basis of clinical cure. Criteria for noninferiority on the basis of microbiologic response and resolution of pyuria were not met.

Archives of Physical Medicine and Rehabilitation 2014;95:290-6

© 2014 by the American Congress of Rehabilitation Medicine.

Urinary tract infection (UTI) is the most common hospital-acquired infection in patients with spinal cord injury (SCI).<sup>1</sup> In general, catheter-associated urinary tract infection (CA-UTI) can lead to serious medical complications, prolong hospitalization, and incur tremendous cost.<sup>2-4</sup> More than 90% of cases of bacteriuria in patients with SCI who use an indwelling bladder catheter are asymptomatic.<sup>5</sup> The rates of CA-UTI differ according to study's definition of UTI and the type of urinary catheters.<sup>6,7</sup> In 1 observational study, the incidence rate of CA-UTI and catheter-associated asymptomatic bacteriuria was 2.7 and 5 cases per 100 person-days, respectively.<sup>8</sup>

The management of CA-UTI has not been standardized in patients with SCI with respect to (1) the need to immediately replace the indwelling catheter, (2) the necessity to provide antibiotic coverage against all organisms grown from urine cultures, and (3) the duration of antibiotic treatment. The Infectious Disease Society of America has published guidelines for the diagnosis and management of CA-UTI.<sup>6</sup> These guidelines recommend early urinary catheter discontinuation and 7- to 14-day antibiotic regimen to treat UTIs in patients with chronic indwelling bladder catheters.

The role of catheter discontinuation was evaluated in 1 randomized controlled trial.<sup>9</sup> Twenty-seven catheterized nursing home patients were randomized to either catheter replacement

or no replacement. Patients who underwent catheter replacement had higher rates of clinical improvement and lower rates of symptomatic relapse. However, the need to remove the urinary catheter was not specifically examined in patients with SCI.

Other studies have evaluated the duration of antibiotic therapy for CA-UTI. These studies have shown conflicting results as to whether a shorter antibiotic regimen was as effective as a longer one. In 1 study,<sup>10</sup> 32 catheterized patients with lower urinary tract symptoms were randomized to receive a single dose of trimethoprim-sulfamethoxazole versus a 10-day therapy. One single dose was as effective as a 10-day regimen in the resolution of symptoms, especially in women <65 years. Another study compared a 3-day course with a 10-day course of antimicrobials for treatment of CA-UTI in 46 intermittently catheterized patients with a neurogenic bladder.<sup>4</sup> Both groups had similar rates of cure, microbiologic persistence, and relapse. A third randomized controlled trial compared a 3-day course with a 14-day course of ciprofloxacin in SCI patients with CA-UTI and demonstrated similar clinical response between the 2 groups.<sup>11</sup> Although patients who received a 14-day regimen had higher rates of microbiologic response and lower rates of clinical and microbiologic recurrence than those who received a 3-day regimen, the results of the study raised the possibility that a 2-week antibiotic regimen may not be necessary, and a shorter antibiotic regimen that exceeds 3 days could be sufficient. In a fourth trial, intermittently catheterized patients with a neurogenic bladder and UTI were randomized to a 5-day course of levofloxacin or a 10-day course of ciprofloxacin.<sup>12</sup> Microbiologic response among catheterized patients was higher in the levofloxacin group (5d) than the

Supported in part by the Department of Veterans Affairs, Rehabilitation Research and Development (grant no. B4747P) and the Dan L. Duncan Institute for Clinical and Translational Research. Clinical Trial Registration No.: NCT00732238.

No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

Download English Version:

<https://daneshyari.com/en/article/3449040>

Download Persian Version:

<https://daneshyari.com/article/3449040>

[Daneshyari.com](https://daneshyari.com)